NCT06984926

A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 3810477 in Healthy Male and Female Trial Participants (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 3810477 in healthy male and female trial participants when given as multiple rising doses.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 3810477	BI 3810477
DRUG	Placebo	Placebo for BI 3810477

Timeline

• Start date: 2025-06-06
• Primary completion: 2026-03-09
• Completion: 2026-03-09
• First posted: 2025-05-22
• Last updated: 2026-03-19

Locations

1 site across 1 country: Belgium